Axalta beats Q2 estimates and reaffirms merger timeline ahead of August 5 vote
AXTA sits 39% above its 52-week low of $24.937.
Summary
Axalta reported better-than-expected Q2 2026 results, with adjusted EBITDA up 5% and adjusted EPS up 13%, while reaffirming the AkzoNobel merger timeline and synergy targets ahead of the August 5 shareholder vote.
Key Events · M&A and Partnerships · AXTA
-
Q2 Earnings Beat
Adjusted EBITDA rose 5% to $305M on 3% higher net sales of $1.35B; adjusted diluted EPS jumped 13% to $0.72, driven by lower operating expenses and favorable price/mix.
-
Merger Costs Impact Net Income
GAAP net income fell 19% to $89M, weighed down by $31M in incremental merger-related costs tied to the AkzoNobel transaction.
-
Cash Flow Strength
Operating cash flow improved 7% to $152M, and free cash flow grew 6% to $107M, supported by better working capital management and lower interest payments.
-
Merger Vote Set for August 5
Axalta and AkzoNobel shareholder meetings are scheduled for August 5, 2026; the presentation reaffirms the deal is on track for closing in late 2026 to early 2027, pending regulatory approvals.
Analysis · AXTA · Industrial Applications And Services
A solid second quarter saw adjusted EBITDA climb 5% and adjusted EPS jump 13%, comfortably ahead of expectations. Even after absorbing $31 million in merger-related costs, free cash flow still expanded 6%. With the AkzoNobel merger vote just eight days away, these results strengthen the deal's strategic case and could tip the balance for undecided shareholders. The presentation reiterates the $600 million synergy target and a late 2026–early 2027 closing, signaling confidence that regulatory approvals remain on track.
At the time of this filing, AXTA was trading at $34.73 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $24.94 to $35.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.